March 23, 2021, Miami — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]
denovoMATRIX Launches New Enabling Technology for High-Quality Induced Pluripotent Stem Cell Culture
DRESDEN, Germany, Mar. 22, 2021 (BioInformant) — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced the launch of a new range of products for the expansion, banking and maintenance of induced pluripotent stem cells (iPSC). The product line, termed myMATRIX iPSC, are chemically defined, ready-to-use consumables, designed to simplify and accelerate iPSC culture. [Read more…]
USPTO Issues New Patents for Cell Source’s Veto Cell Technology
Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections
March 19, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the Company”), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ transplants. In addition, Veto Cells can durably treat malignant and non-malignant blood diseases through active immune response management. Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. [Read more…]
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
FLORHAM PARK, N.J., March 18, 2021 — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM. [Read more…]
Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients
Organicell Regenerative Medicine (OTCBB: BPSR), a clinical-stage biopharma company developing exosome-based regenerative therapies, has announced the release of a Case Report in the peer reviewed journal Frontiers in Medicine. This case study highlights the therapeutic potential of Organicell’s proprietary therapeutic, Zofin™, and its continued success as a drug candidate. [Read more…]
- « Previous Page
- 1
- …
- 165
- 166
- 167
- 168
- 169
- …
- 334
- Next Page »